Opinion|Videos|February 24, 2025
Oral Systemic Treatment Options for a 28-Year-Old Woman With Moderate Atopic Dermatitis
Author(s)Raj Chovatiya, MD, PhD, MSCI
The panelist discusses how a 28-year-old woman with moderate atopic dermatitis requires personalized, comprehensive management addressing hand involvement, corticosteroid concerns, and potential Janus kinase (JAK) inhibitor therapy, focusing on symptom relief, safety, and patient-specific factors.
Advertisement
Episodes in this series
Video content above is provided by the following:
- Please provide your initial impressions of this case. Does the involvement of the patient’s hands influence your management plan at all?
- How would you address the patient’s concerns regarding potential adverse effects of topical corticosteroids?
- Describe your approach to treatment options for this patient. What patient-specific factors would you take into consideration when deciding on a treatment?
- In what scenarios would a JAK inhibitor be preferred over another systemic agent?
- How would decide between a topical or systemic JAK inhibitor for a patient?
- What can the patient expect in terms of efficacy and safety with upadacitinib? When should she expect initial symptom relief?
Advertisement
Related to this article
A retrospective claims analysis of 2897 matched pairs found hazard ratios of 0.48 to 0.67 for new atopic disease with dupilumab vs systemic corticosteroids in children.
SYX-5219 improved disease severity and itch in a Phase 1b trial of adults with moderate to severe atopic dermatitis.
Christophe Piketty discusses 3-year ARCADIA data demonstrating sustained efficacy and long-term safety of nemolizumab in atopic dermatitis.
No skin lesion flares were observed through 16 weeks after switching from dupilumab to upadacitinib; itch flares occurred in 3.6% to 4.8% of patients with baseline WP-NRS scores of 6 or lower.
Three-year ARCADIA LTE data show sustained skin clearance and itch control with nemolizumab in moderate-to-severe atopic dermatitis.
Upadacitinib showed broader inflammatory effects and earlier skin barrier restoration than dupilumab in atopic dermatitis.
Advertisement
Advertisement
Trending on Dermatology Times
1
Bitopertin Meets All End Points in Phase 3 APOLLO Trial for EPP
2
Social Media Mythbusters: Can Castor Oil Really Grow Hair?
3
EADV 2026 Atopic Dermatitis Highlights: Tilrekimig, RAC2 Inhibition, and Level Up Data
4
Dupilumab Associated With Lower Atopic March Risk in Pediatric Atopic Dermatitis
5